YASMEEN ALSAQRI: Open Payments
NPI 1366153785 · ENFIELD, CT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,280 in 145 payments from 34 companies in 2025. Trend: 2023 $1,983 · 2024 $2,305 · 2025 $3,280
Food & beverage: $3,280
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 17 | $340 |
| Novo Nordisk Inc | 20 | $332 |
| Indivior Inc. | 9 | $269 |
| GlaxoSmithKline, LLC. | 13 | $257 |
| ABBVIE INC. | 10 | $214 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $178 |
| Otsuka America Pharmaceutical, Inc. | 7 | $175 |
| Lilly USA, LLC | 7 | $174 |
| Amgen Inc. | 5 | $118 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $115 |
Products named: SUBLOCADE, REXULTI, Wegovy, BREZTRI, TRELEGY ELLIPTA, JARDIANCE, TRINTELLIX, VRAYLAR.
Industry payments across CT — which companies pay providers there.
